Global Amyloidosis Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

The global amyloidosis treatment market is segmented by type into AL amyloidosis, AA amyloidosis, hereditary ATTR amyloidosis, wild-type ATTR amyloidosis, and others. AL amyloidosis, the most common type, is driven by the abnormal production of amyloid proteins from plasma cells, often treated with chemotherapy and stem cell transplants. AA amyloidosis, linked to chronic inflammatory diseases, primarily requires supportive care and anti-inflammatory treatments. Hereditary ATTR and wild-type ATTR amyloidosis are increasingly being targeted with novel therapies, including RNA-targeting and stabilizing agents, contributing to the growth of advanced treatment options.

By treatment, the market includes chemotherapy, supportive care, surgery, stem cell transplant, and targeted therapy. Chemotherapy remains a cornerstone for managing AL amyloidosis, while supportive care is essential for symptom management and improving patient quality of life across all amyloidosis types. Stem cell transplantation is a key option for eligible patients, offering potential remission. Targeted therapies, such as monoclonal antibodies and gene-silencing drugs, are gaining momentum due to their precision in addressing specific disease mechanisms, particularly for ATTR amyloidosis.

The end-use segment comprises hospitals and clinics, ambulatory surgical centers, home care settings, and others. Hospitals and clinics dominate due to their capacity to deliver complex treatments and handle critical cases. Ambulatory surgical centers are emerging as a convenient option for outpatient procedures, including diagnostic biopsies and minor interventions. Home care settings are becoming more relevant for long-term care and supportive treatment, providing patients with the comfort of receiving care in familiar surroundings. Geographically, North America leads the market due to advanced healthcare infrastructure and research activities, followed by Europe and the Asia Pacific, which show significant growth potential due to rising awareness and healthcare investments.

Global Amyloidosis Treatment Segment Analysis

In this report, the Global Amyloidosis Treatment Market has been segmented by Type, Treatment, End-use and Geography.

Global Amyloidosis Treatment Market, Segmentation by Type

The Global Amyloidosis Treatment Market has been segmented by Type into AL Amyloidosis, AA Amyloidosis, Hereditary ATTR Amyloidosis, Wild-type ATTR Amyloidosis, and Others.

The Global Amyloidosis Treatment Market has seen substantial growth in recent years, driven by advancements in diagnostic techniques and the introduction of novel therapeutics. Amyloidosis, a rare disease characterized by the abnormal deposition of amyloid proteins in various tissues and organs, presents significant treatment challenges. The market is segmented into several types based on the amyloidosis variants: AL (light-chain) amyloidosis, AA (secondary) amyloidosis, hereditary ATTR (transthyretin) amyloidosis, wild-type ATTR amyloidosis, and others, each requiring distinct therapeutic approaches.

AL amyloidosis is the most common form and occurs when an abnormal protein called light chain builds up in tissues. Treatment for AL amyloidosis typically involves chemotherapy to suppress the production of amyloid proteins by targeting the underlying plasma cell disorder. The market for AL amyloidosis treatments is bolstered by the availability of established drugs like bortezomib and the increasing use of stem cell transplantation. The rising prevalence and improved diagnostic capabilities contribute significantly to the market growth in this segment.

AA amyloidosis, which is often secondary to chronic inflammatory diseases like rheumatoid arthritis or chronic infections, is another significant segment. The treatment primarily focuses on controlling the underlying condition to reduce amyloid protein production. The availability of biologics and disease-modifying antirheumatic drugs (DMARDs) has been pivotal in managing AA amyloidosis. The market for AA amyloidosis treatments is expected to grow as awareness increases and more effective anti-inflammatory therapies become available.

Hereditary ATTR amyloidosis and wild-type ATTR amyloidosis are less common but equally important segments. Hereditary ATTR amyloidosis is caused by mutations in the transthyretin gene, leading to amyloid deposits in various organs. New therapeutic options, such as TTR stabilizers and gene-silencing drugs, have significantly improved patient outcomes. Wild-type ATTR amyloidosis, which occurs without genetic mutations and typically affects the elderly, is treated with similar approaches. The introduction of innovative treatments like patisiran and inotersen, along with ongoing clinical trials, is expected to drive growth in these segments. Overall, the Global Amyloidosis Treatment Market is poised for continued expansion, driven by advancements in treatment modalities and increased disease awareness.

Global Amyloidosis Treatment Market, Segmentation by Treatment

The Global Amyloidosis Treatment Market has been segmented by Treatment into Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant and Targeted Therapy.

The global amyloidosis treatment market is witnessing significant growth, driven by advancements in medical technology, increasing awareness about amyloidosis, and rising incidences of amyloidosis-related disorders worldwide. The market has been segmented by treatment into chemotherapy, supportive care, surgery, stem cell transplant, and targeted therapy, reflecting the diverse approaches in managing this complex disease.

Chemotherapy remains a cornerstone in the treatment of amyloidosis, particularly for patients with systemic forms of the disease. It aims to halt the production of abnormal proteins and alleviate symptoms associated with organ damage. Supportive care plays a crucial role in managing complications and improving the quality of life for amyloidosis patients. This includes symptom management, nutritional support, and organ-specific interventions.

Surgery may be necessary in certain cases, especially when amyloid deposits cause structural damage to organs such as the heart or nerves. Surgical interventions aim to repair or remove affected tissues to restore function and alleviate symptoms. Stem cell transplant, also known as bone marrow transplant, offers a potential cure for select patients with certain types of amyloidosis. It involves replacing diseased bone marrow with healthy stem cells to produce normal blood cells.

Targeted therapy represents a promising approach in amyloidosis treatment, focusing on specific molecular targets involved in the disease process. This includes monoclonal antibodies and small molecule inhibitors designed to block the production or deposition of abnormal proteins, thereby slowing disease progression and reducing organ damage.

The global amyloidosis treatment market is characterized by ongoing research efforts to develop more effective therapies and improve patient outcomes. With continued innovation and collaboration across the healthcare industry, there is optimism for better management and potential cures for this challenging condition.

Global Amyloidosis Treatment Market, Segmentation by End-use

The Global Amyloidosis Treatment Market has been segmented by End-use into Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others.

The global amyloidosis treatment market is segmented by end-user into hospitals and clinics, ambulatory surgical centers, home care settings, and others. Hospitals and clinics dominate the market due to their comprehensive diagnostic capabilities and availability of specialized care for amyloidosis patients. These facilities often serve as primary treatment centers, offering advanced therapies such as chemotherapy, immunotherapy, and stem cell transplantation, which are essential for managing the complex nature of the disease.

Ambulatory surgical centers are emerging as a significant segment, particularly for outpatient procedures and supportive treatments. These centers are increasingly being utilized for minor interventions, diagnostic biopsies, or follow-up therapies. Their cost-effectiveness and patient-centric approach, coupled with shorter waiting times, make them a viable option for certain stages of amyloidosis care, driving their adoption in the healthcare landscape.

Home care settings are gaining traction, especially for patients requiring long-term care and symptom management. These settings enable the administration of medications, palliative care, and nutritional support in a familiar environment, improving patient comfort and quality of life. The "others" category encompasses research institutions and specialty centers focusing on clinical trials and innovative therapies, contributing to advancements in amyloidosis treatment and expanding the overall market scope.

Global Amyloidosis Treatment Market, Segmentation by Geography

In this report, the Global Amyloidosis Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Amyloidosis Treatment Market Share (%), by Geographical Region, 2024

The global amyloidosis treatment market is witnessing significant growth, driven by a rise in the prevalence of amyloidosis worldwide. Amyloidosis is a group of rare diseases characterized by the abnormal accumulation of amyloid protein in various organs and tissues, leading to organ dysfunction and failure. The market is segmented by geography into five key regions: North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

North America holds the largest share of the amyloidosis treatment market, attributed to factors such as well-established healthcare infrastructure, high prevalence rates of amyloidosis, and increasing awareness among patients and healthcare professionals. Moreover, the presence of key market players and ongoing research and development activities contribute to the region's dominance in the market.

Europe follows North America in terms of market share, with a considerable presence of pharmaceutical companies focusing on amyloidosis treatment. The region also benefits from supportive government initiatives and reimbursement policies, driving market growth.

The Asia Pacific region is expected to witness rapid growth in the amyloidosis treatment market due to factors such as improving healthcare infrastructure, increasing healthcare expenditure, and rising awareness about rare diseases. Additionally, the large population base in countries like China and India presents significant opportunities for market expansion.

The Middle East and Africa, along with Latin America, are also projected to experience growth in the amyloidosis treatment market, supported by increasing healthcare spending, improving access to healthcare services, and rising awareness about amyloidosis among both patients and healthcare providers. However, challenges such as limited access to advanced treatment options and healthcare disparities may hinder market growth in these regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Amyloidosis Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers:

• Increasing disease prevalence worldwide
• Advancements in diagnostic techniques
• Growing awareness initiatives globally
• Rising healthcare expenditure internationally

• Improved therapeutic options available: The global amyloidosis treatment market has witnessed significant advancements in recent years, driven by the development of improved therapeutic options. Traditional treatment methods, such as chemotherapy and autologous stem cell transplants, have been complemented by novel targeted therapies that offer better outcomes with fewer side effects. These new therapies include monoclonal antibodies like daratumumab, which specifically target amyloid fibrils, and RNA interference (RNAi) drugs such as patisiran and inotersen, which inhibit the production of amyloidogenic proteins. The approval of these targeted treatments has not only expanded the therapeutic arsenal against amyloidosis but also provided patients with more personalized and effective treatment regimens.

  The market growth is bolstered by ongoing research and clinical trials aimed at identifying and developing new therapeutic agents. Pharmaceutical companies are investing heavily in the discovery of small molecules, gene therapies, and other innovative approaches to address the underlying mechanisms of amyloidosis. Additionally, increased awareness and early diagnosis of the disease have contributed to the rising demand for these advanced treatments. As a result, the amyloidosis treatment market is expected to grow robustly, providing hope for improved patient outcomes and a better quality of life for those affected by this complex and often debilitating condition.

Restraints:

• High treatment costs
• Limited treatment accessibility
• Stringent regulatory approvals
• Side effects of drugs

• Lack of skilled professionals: The global amyloidosis treatment market is facing a significant challenge due to the lack of skilled professionals. Amyloidosis, a rare and complex disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, requires highly specialized knowledge for effective diagnosis and treatment. The scarcity of healthcare professionals with expertise in this area leads to delays in diagnosis, misdiagnosis, and suboptimal treatment outcomes. This shortage is particularly acute in developing regions, where medical infrastructure and training programs may be less advanced. Consequently, patients in these areas often have limited access to advanced diagnostic tools and specialized care, exacerbating the overall burden of the disease.

  The intricate nature of amyloidosis demands continuous education and training for healthcare providers to stay updated with the latest advancements in diagnostic techniques and therapeutic options. The rapid pace of medical research and the introduction of novel treatment modalities, such as targeted therapies and gene-editing technologies, further underscore the need for a well-trained workforce. Addressing this gap requires concerted efforts from medical institutions, industry stakeholders, and government bodies to enhance educational programs, provide incentives for specialization in rare diseases, and facilitate international collaborations. Such measures are crucial to improving patient outcomes and ensuring that advancements in amyloidosis treatment can be effectively translated into clinical practice globally.

Opportunities:

• Emerging market expansion
• Technological advancements in treatment
• Collaborative research initiatives
• Personalized medicine development

• Government funding support: The global amyloidosis treatment market has been experiencing significant growth, driven by advancements in medical research and increasing awareness of the disease. Amyloidosis, characterized by the abnormal accumulation of amyloid proteins in organs and tissues, requires complex and often costly treatment regimens. Government funding plays a crucial role in supporting research and development (R&D) efforts aimed at discovering new therapies and improving existing ones. This financial backing is essential for conducting clinical trials, which are critical for the approval of new treatments by regulatory bodies. Governments across various countries, including the United States, European Union nations, and Japan, have been actively investing in amyloidosis research initiatives, providing grants and subsidies to academic institutions, biotechnology companies, and pharmaceutical firms. Such funding not only accelerates the pace of innovation but also ensures that new treatments are accessible to patients sooner.

  In addition to supporting R&D, government funding also facilitates public health initiatives aimed at early diagnosis and patient education. By investing in awareness campaigns and screening programs, governments can help identify amyloidosis cases at an earlier stage, allowing for timely intervention and better management of the disease. For instance, the National Institutes of Health (NIH) in the United States has been instrumental in promoting research on rare diseases, including amyloidosis, through various funding mechanisms. Similarly, the European Union's Horizon Europe program provides substantial grants for collaborative research projects focused on rare diseases. These efforts are crucial in addressing the unmet medical needs of amyloidosis patients, ultimately improving their quality of life and reducing the long-term burden on healthcare systems. As a result, government funding support is a key driver in the growth and development of the global amyloidosis treatment market.

Key players in Global Amyloidosis Treatment Market include:

• Pfizer Inc.
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Prothena Corporation plc
• Alnylam Pharmaceuticals, Inc.
• Eidos Therapeutics
• Ionis Pharmaceuticals, Inc.
• GlaxoSmithKline plc
• Bristol Myers Squibb
• Novartis International AG
• Teva Pharmaceutical Industries Ltd.
• Caelum Biosciences
• Pfizer
• Ionis Pharmaceuticals
• AbbVie Inc.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis